EP3731806B1 - Verfahren zur herstellung eines füllstoffs mit einer hyaluronsäurebasis - Google Patents

Verfahren zur herstellung eines füllstoffs mit einer hyaluronsäurebasis Download PDF

Info

Publication number
EP3731806B1
EP3731806B1 EP17859346.3A EP17859346A EP3731806B1 EP 3731806 B1 EP3731806 B1 EP 3731806B1 EP 17859346 A EP17859346 A EP 17859346A EP 3731806 B1 EP3731806 B1 EP 3731806B1
Authority
EP
European Patent Office
Prior art keywords
hyaluronic acid
comprised
containers
filler
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17859346.3A
Other languages
English (en)
French (fr)
Other versions
EP3731806A1 (de
Inventor
Nicola Zerbinati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matex Lab SpA
Original Assignee
Matex Lab SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matex Lab SpA filed Critical Matex Lab SpA
Publication of EP3731806A1 publication Critical patent/EP3731806A1/de
Application granted granted Critical
Publication of EP3731806B1 publication Critical patent/EP3731806B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/82—Preparation or application process involves sonication or ultrasonication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Definitions

  • Embodiments described here concern a method to prepare a filler with a hyaluronic acid base, which has better properties of chemical and physical stability over time and optimal viscoelasticity to be injected cutaneously.
  • the method according to the embodiments described here concerns a method to prepare a filler with a hyaluronic acid base (HA), which comprises a first step in which the hyaluronic acid is crosslinked and a subsequent step to neutralize and hydrate the crosslinked hyaluronic acid.
  • HA hyaluronic acid base
  • hyaluronic acid is one of the fundamental components of the connective tissues of man and other mammals. It is a substance widely present in the human body in the epidermal, epithelial and neural tissues.
  • Hyaluronic acid gives the skin its peculiar properties of resistance and shape retention. A lack of hyaluronic acid causes a weakening of the skin, promoting the formation of wrinkles and imperfections.
  • the concentration of hyaluronic acid in the tissues of the human body tends to decrease with advancing age, so that its function of tissue repair is weakened.
  • the epidermal cells decrease their production of hyaluronic acid and their speed of degradation increases.
  • the skin loses collagen, which is another natural substance necessary for maintaining the skin in a young and resilient form.
  • the loss of hyaluronic acid and collagen in the epidermal tissues causes the formation of folds and wrinkles.
  • hyaluronic acid is a polymer compound, definable as a glycosaminoglycan with an un-branched polysaccharide chain, produced by the condensation of thousands of disaccharide units, which are in turn formed by residues of glucuronic acid and M-acetylglucosamine.
  • the molecule of the salt corresponding to hyaluronic acid that is, hyaluronate, is able to complex with many molecules of water reaching a high degree of hydration.
  • the extreme length of the hyaluronic acid molecule and its high degree of hydration allow the molecules to organize themselves to form a structure of the lattice type (crosslinked hyaluronic acid), so as to create a molecular scaffold to maintain the shape and tone of the epidermal tissue.
  • Hyaluronic acid being naturally contained in the human body, is a filler that is well tolerated by the epidermal tissue. For this reason, the formulations based on HA are still today considered the best epidermal fillers on the market, because they do not carry the risk of allergic reactions by the skin.
  • the first formulations based on hyaluronic acid were prepared in the form of particles or microspheres suspended in a gel.
  • these fillers based on gelled microspheres had the disadvantage of poor stability over time, with a tendency to chemical degradation a few months after being injected into the skin. Therefore, frequent re-injections of the filler were required over time, in order to maintain the repair and epidermal growth constant.
  • crosslinking agents we can cite 1,4-butanediol diglycidyl ether (BDDE), 1,2-ethanediol diglycidyl ether (EDDE), diepoxyoctane and divinyl sulfone.
  • BDDE 1,4-butanediol diglycidyl ether
  • EDDE 1,2-ethanediol diglycidyl ether
  • the crosslinking step allows to obtain a hydrogel polymer lattice, which is less soluble in water and more resistant to degradation, so as to require less frequent cutaneous injections than in the case of formulations based on non-crosslinked hyaluronic acid.
  • crosslinking agents leads to the formation of hydrogels of crosslinked HA which have an excessive level of swelling of the lattice, in the step where the hyaluronic acid is contacted with a chemical neutralizing solution.
  • an important disadvantage deriving from the crosslinking operating conditions adopted in the state of the art is the formation of fillers based on crosslinked HA with a poor homogeneity of distribution of the chemical-physical parameters (temperature, viscosity, density, etc.) inside the polymer lattice, in the sense that the homogeneity of the structure is interrupted by the unwanted presence of both air microbubbles and lumps of material, that is, narrow zones of thickened material.
  • a second purpose of the method according to the invention is to obtain a filler with a crosslinked HA base having adjustable viscoelasticity in a desired range, by controlling the parameters that define the crosslinking of hyaluronic acid and the subsequent hydration step.
  • Another purpose of the invention is to improve the efficiency of penetration of a neutralizing solution in the chemical neutralization step that follows the crosslinking of the hyaluronic acid, by means of a selection of innovative operating conditions during the neutralization step.
  • the Applicant has devised, tested and embodied the present invention to overcome the shortcomings of the state of the art and to obtain these and other purposes and advantages.
  • Embodiments described here concern a method to prepare a filler with a hyaluronic acid (HA) base, which comprises a step in which the hyaluronic acid is crosslinked, and a subsequent step for the neutralization and hydration of the crosslinked hyaluronic acid.
  • HA hyaluronic acid
  • the main advantage of the method claimed is that the operating conditions used allow to obtain formulations with a hyaluronic acid base with innovative and improving characteristics with regard to the homogeneity and uniformity of the different chemical-physical parameters inside it (composition, temperature, viscosity, etc.). Consequently, its chemical-physical stability over time, after cutaneous injection, is considerably increased.
  • a first aspect of the invention concerns a method to prepare a filler with a hyaluronic acid base comprising the crosslinking of the hyaluronic acid by means of the following steps:
  • step A2 The particular operating conditions adopted during the steps A1), A2), A3) described above, in particular the use of a crosslinking agent selected from the polyethylene glycols and the division of the reaction mixture into n partial portions (step A2), lead to the formation of a lattice of hyaluronic acid HA in a gel form with innovative characteristics with respect to the state of the art techniques. Indeed, this lattice of hyaluronic acid will have a much lower level of swelling during the subsequent neutralization and hydration step.
  • Embodiments of the present invention also concern defining optimal operating conditions during the chemical neutralization of the hyaluronic acid gel deriving from the crosslinking step described above.
  • a method to prepare a filler with a hyaluronic acid base is therefore a second aspect of the present invention, and comprises the following steps:
  • step B2 The particular operating conditions adopted during the neutralizing step B), in particular the division (step B2) of the neutralizing solution into a number n of partial portions, and the subsequent gentle rotation to which the n containers are subjected during step B3), allow to improve the penetration efficiency of the neutralizing solution inside the crosslinked HA gel. Consequently, an improved homogeneity and uniformity of chemical-physical parameters inside the filler obtained is obtained.
  • a third aspect of the present invention also concerns a specific embodiment of the method to prepare a filler with a hyaluronic acid base, which method comprises:
  • the method according to the embodiments described here allows to suitably adjust the final viscoelasticity of the filler prepared.
  • the control of the crosslinking parameters and the subsequent hydration step of the gel makes the product stable from the thermodynamic point of view, so that the rheology of the product is also adjusted and maintained under control.
  • the adjustment of the final viscoelasticity of the hyaluronic acid filler allows, in the case of very viscous fillers, to be able to select the type of syringe most suitable for viscous fluids, so that the cutaneous injection can be performed without particular disadvantages linked to high viscosity.
  • Embodiments of the present invention also concern the use of lidocaine or its derivatives as an anesthetic agent during the chemical neutralization step of the hyaluronic acid gel.
  • a method to prepare a filler with a hyaluronic acid base is thus another aspect of the invention, which comprises the following steps:
  • the present description also includes the intervals that derive from uniting or overlapping two or more intervals described, unless otherwise indicated.
  • the present description also includes the intervals that can derive from the combination of two or more values taken at different points, unless otherwise indicated.
  • Embodiments described here concern the preparation of a filler with a hyaluronic acid base which can be used in the cosmetic treatment of the face, in particular to fill wrinkles, folds and scars and, in general, to improve the appearance of the face.
  • the crosslinking step A) is carried out by crosslinking agents selected from polyethylene glycols (PEG).
  • the crosslinking step A) comprises a sequence of at least three steps A1), A2) and A3).
  • Sub-step A1) involves mixing the following components in a reaction chamber: water, hyaluronic acid (HA), a crosslinking agent selected from the polyethylene glycol class (PEG), a solution of alkali metal hydroxide.
  • HA hyaluronic acid
  • PEG polyethylene glycol class
  • the mixing step A1) of the above components is carried out at a temperature between 10°C and 30°C, preferably between 15°C and 25°C, with a mixing time conveniently comprised between 10 and 40 minutes, preferably between 15 and 25 minutes.
  • the percentage by weight (w/w) of the individual components with respect to the total weight of the mixture can be as follows:
  • the mixing step A1) of the components indicated can be carried out in two successive steps.
  • a first step we have the preliminary mixing of water, hyaluronic acid (HA) fed in excess of the water, and a polyethylene glycol with a mixing time maintained between 2 and 6 minutes.
  • HA hyaluronic acid
  • the solution of alkali metal hydroxide preferably sodium hydroxide NaOH
  • the mixing of the components is continued for a time comprised between 8 and 25 minutes, preferably between 10 and 20 minutes.
  • the mixture obtained is divided into a number n of partial portions, where n is a whole number comprised between 4 and 32, preferably between 8 and 20.
  • n is a whole number comprised between 4 and 32, preferably between 8 and 20.
  • the ultrasound treatment of the n containers is carried out by means of sound waves with a frequency comprised between 40 and 60 kHz.
  • the step A2) of ultrasound treatment is generally carried out at a temperature comprised between 20 and 30°C, for a duration comprised between 5 and 15 minutes.
  • the ultrasound treatment with the above operating conditions proved to be particularly effective for separating and removing the air microbubbles, which can form during the mixing steps, from the mixture.
  • the air microbubbles represent zones of discontinuity of material inside the formulation obtained, and therefore their presence could compromise the final viscoelastic properties of the filler prepared.
  • the n containers comprising the n partial portions of mixture are disposed inside an incubator to complete the crosslinking reaction between the hyaluronic acid and the polyethylene glycol, that is, performing step A3) of the method in accordance with the present description.
  • the temperature is set to a constant value comprised between 25°C and 35°C
  • the n containers are left inside the incubator for a period of time comprised between 4 and 8 hours, preferably between 5 and 7 hours.
  • the crosslinking of the hyaluronic acid can be defined as terminated, so that a crosslinked hyaluronic acid gel is obtained inside each container.
  • the crosslinking step A) is carried out in a basic environment due to the presence of a strong base such as sodium hydroxide: therefore, at the end of the crosslinking, hyaluronic acid is obtained in gel form having a pH comprised between 10 and 14.
  • the gelled formulation obtained absolutely cannot be used for esthetic treatments, as it would cause swelling and burning to the skin, besides being thermodynamically unstable.
  • hydrolysis phenomena become likely, which are able to degrade the chemical structure of the hyaluronic acid hydrogel.
  • the subsequent step B) of neutralizing the HA gel therefore becomes necessary, using a strong acid such as hydrochloric acid.
  • the neutralization step B) also comprises a sequence of sub-steps B1), B2) and B3).
  • a neutralizing solution is prepared by mixing the following components: water, hydrochloric acid HCl and a buffer agent.
  • the percentage by weight (w/w) of the individual components with respect to the total weight of the neutralizing solution is as follows:
  • phosphoric acid potassium phosphate, sodium phosphate can be used.
  • phosphoric acid is used.
  • the neutralizing solution can optionally also comprise small quantities of lidocaine or its derivatives, preferably lidocaine hydrochloride is used.
  • lidocaine hydrochloride is used.
  • This category of compounds are known for their local anesthetic effect, so they have the advantage of reducing itching or burning of the skin during the subcutaneous injection of HA filler.
  • the percentage by weight (w/w) of lidocaine or its derivatives, with respect to the total weight of the solution is generally maintained below 1.5%.
  • the neutralizing solution can optionally also comprise small quantities of glycine and/or proline.
  • glycine and/or proline are two amino acids that have the dual function of acting as thermodynamic stabilizers of the solution, and of being precursors of the formation of collagen, thus increasing the efficiency of the filler prepared in repairing the tissues.
  • the total percentage by weight (w/w) of proline and/or glycine with respect to the weight of the neutralizing solution is generally maintained below 1%.
  • step B2 it is convenient to divide (step B2) the neutralizing solution into a number n of partial portions, in the same way as in step A2), n being a whole number comprised between 4 and 32, preferably between 8 and 20.
  • the partial portions n of neutralizing solution are then transferred into the n containers comprising the crosslinked HA gel obtained from step A).
  • step B3 which consists in mixing the contents of the n containers using a rotating device: the n containers are put in a gentle rotation around the axis of the rotating device for a duration comprised between 140 and 200 hours.
  • the temperature is maintained at a value comprised between 20°C and 30°C, while the speed of rotation of the n containers around the axis of the rotating device is maintained at a rather low value, generally comprised between 40 and 60 rpm.
  • the hydrogel filler of crosslinked hyaluronic acid obtained from step B) has a complex viscosity that can be comprised between 15 and 45 Pa ⁇ s (measured by Kinexus rheometer at 25°C).
  • the HA filler in the form of hydrogel obtained in step B) is then subjected to a pH control to verify the effectiveness of the chemical neutralization that has taken place. Consequently, the pH value inside the n containers must be neutral, that is, comprised in a range between 6.5 and 7.5.
  • the hydrogel filler of crosslinked HA prepared by the method described here is suitable to be inserted inside cartridges for syringes for cutaneous injection.
  • the filler storage cartridges Before being used, the filler storage cartridges have to be subjected to sterilization in autoclave. Autoclave sterilization is performed for 16 minutes at a temperature of 121°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)

Claims (10)

  1. Verfahren zur Herstellung eines Füllstoffs mit einer Hyaluronsäure-Basis, umfassend:
    A) einen Schritt der Vernetzung der Hyaluronsäure, umfassend die folgenden Schritte:
    A1) Mischen der folgenden Komponenten (Gew./Gew.) in einer Reaktionskammer für einen Zeitraum von 10 bis 40 Minuten:
    - 25 bis 60 Gew.-% Wasser;
    - 6 bis 18 Gew.-% Hyaluronsäure;
    - 25 bis 60 Gew.-% einer Lösung eines Alkalimetallhydroxids;
    - 0,5 bis 4 Gew.-% eines Vernetzungsmittels ausgewählt aus der Klasse der Polyethylenglycole;
    A2) Aufteilen der so erhaltenen Mischung in eine Anzahl von n Teilmengen und Überführen der Teilmengen in eine Reihe von n Behältern, um sie einer Ultraschallbehandlung zu unterziehen, wobei die Anzahl n der Teilmengen und Behälter 4 bis 32 beträgt;
    A3) Platzieren der die Teilmengen der Mischung enthaltenden n Behälter in einem Inkubator für einen Zeitraum von 4 bis 8 Stunden;
    B) einen Schritt der chemischen Neutralisation des Gels der in Schritt A) erhaltenen, vernetzten Hyaluronsäure HA, umfassend die folgenden Schritte:
    B1) Herstellen einer Neutralisationslösung durch Mischen der folgenden Komponenten (Gew./Gew.):
    - 78 bis 98 Gew.-% Wasser;
    - 4 bis 25 Gew.-% Salzsäure;
    - 0,1 bis 1,5 Gew.-% eines Puffermittels;
    - bis zu 1,5 Gew.-% Lidocain oder Derivaten davon;
    B2) Aufteilen der so erhaltenen Neutralisationslösung in eine Anzahl von n Teilmengen und Überführen der Teilmengen in die n Behälter, welche das in Schritt A) erhaltene Gel der vernetzten Hyaluronsäure HA enthalten, wobei n eine ganze Zahl von 4 bis 32 ist;
    B3) Durchmischen der n Behälter mit Hilfe einer Rotationsvorrichtung, wobei sie um die Achse der Rotationsvorrichtung rotiert werden, so dass ein Eindringen der Neutralisationslösung in das Hyaluronsäure-Gel gefördert wird und ein Füllstoff aus vernetzter Hyaluronsäure in Form von Hydrogel erhalten wird.
  2. Verfahren gemäß Anspruch 1, dadurch gekennzeichnet, dass in dem Mischschritt A1) die Temperatur 10 °C bis 30 °C beträgt.
  3. Verfahren gemäß Anspruch 1, dadurch gekennzeichnet, dass in Schritt A1) die Mischzeit 10 bis 40 Minuten beträgt.
  4. Verfahren gemäß irgendeinem vorhergehenden Anspruch, dadurch gekennzeichnet, dass das Vernetzungsmittel aus bifunktionalen PEGs, welche zwei Epoxygruppen am Ende der Polymerkette aufweisen, ausgewählt ist.
  5. Verfahren gemäß irgendeinem vorhergehenden Anspruch, dadurch gekennzeichnet, dass die Anzahl n der Behälter 8 bis 20 beträgt.
  6. Verfahren gemäß irgendeinem vorhergehenden Anspruch, dadurch gekennzeichnet, dass in Schritt B3) die Rotation der n Behälter um die Achse der Rotationsvorrichtung bei einem Wert von 40 bis 60 rpm gehalten wird.
  7. Verfahren gemäß irgendeinem vorhergehenden Anspruch, dadurch gekennzeichnet, dass während des Durchmischungsschritts B3) die Temperatur bei einem Wert von 20 °C bis 30 °C gehalten wird.
  8. Verfahren gemäß irgendeinem vorhergehenden Anspruch, dadurch gekennzeichnet, dass die in Schritt B3) durchgeführte Durchmischung über eine Zeitraum von 140 bis 200 Stunden erfolgt.
  9. Verfahren gemäß irgendeinem vorhergehenden Anspruch, dadurch gekennzeichnet, dass der in Schritt B3) hergestellte Hydrogel-Füllstoff aus Hyaluronsäure eine komplexe Viskosität von 15 bis 45 Pa∗s aufweist.
  10. Verfahren gemäß irgendeinem vorhergehenden Anspruch, dadurch gekennzeichnet, dass der in Schritt B3) hergestellte HA-Füllstoff in Patronen für Injektionsspritzen eingeführt wird, die für 16 Minuten einer Sterilisation in Autoklaven bei 121 °C unterzogen werden.
EP17859346.3A 2017-12-29 2017-12-29 Verfahren zur herstellung eines füllstoffs mit einer hyaluronsäurebasis Active EP3731806B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2017/000297 WO2019130358A1 (en) 2017-12-29 2017-12-29 Method to prepare a filler with a hyaluronic acid base

Publications (2)

Publication Number Publication Date
EP3731806A1 EP3731806A1 (de) 2020-11-04
EP3731806B1 true EP3731806B1 (de) 2022-06-29

Family

ID=61873655

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17859346.3A Active EP3731806B1 (de) 2017-12-29 2017-12-29 Verfahren zur herstellung eines füllstoffs mit einer hyaluronsäurebasis

Country Status (6)

Country Link
US (1) US11491098B2 (de)
EP (1) EP3731806B1 (de)
KR (1) KR102532037B1 (de)
CN (1) CN111918640A (de)
RU (1) RU2756546C1 (de)
WO (1) WO2019130358A1 (de)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105022A1 (en) * 2004-11-15 2006-05-18 Shiseido Co., Ltd. Process for preparing crosslinked hyaluronic acid gel
WO2006051950A1 (ja) * 2004-11-15 2006-05-18 Shiseido Co., Ltd. 架橋ヒアルロン酸ゲルの製造方法
JP2007151468A (ja) 2005-12-06 2007-06-21 Japan Home Supply Kk 加工装置
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US9408797B2 (en) * 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
CN104105474B (zh) * 2011-09-14 2018-04-06 阿勒根公司 用于细纹治疗的真皮填充剂组合物
KR20150008556A (ko) * 2013-07-15 2015-01-23 (주)아크로스 조직수복용 생체재료 제조방법
CN106279726B (zh) 2016-08-09 2019-04-05 北京大清生物技术股份有限公司 交联透明质酸钠凝胶及其制备方法
BR112019004332B1 (pt) * 2016-09-07 2022-09-06 Luminera Derm Ltd Géis injetáveis que compreendem ácido hialurônico reticulado e hidroxiapatita, composição e processo de fabricação dos mesmos

Also Published As

Publication number Publication date
RU2756546C1 (ru) 2021-10-01
CN111918640A (zh) 2020-11-10
US20200330359A1 (en) 2020-10-22
WO2019130358A1 (en) 2019-07-04
EP3731806A1 (de) 2020-11-04
US11491098B2 (en) 2022-11-08
KR20200127986A (ko) 2020-11-11
KR102532037B1 (ko) 2023-05-12

Similar Documents

Publication Publication Date Title
EP3731808B1 (de) Verfahren zur herstellung eines füllstoffs mit einer hyaluronsäurebasis mit einem neutralisationsschritt
EA022478B1 (ru) Когезионный однофазный биоразлагаемый гидрогель, способ его получения и применение
AU2013276844A1 (en) Method of preparing a composition based on hyaluronic acid
JP6827108B2 (ja) 皮膚充填剤用途のためのコアセルベートヒアルロナンヒドロゲル
EP3731807B1 (de) Verfahren zur herstellung eines füllstoffs mit einer hyaluronsäurebasis mit einem neutralisationsschritt
EP3316911B1 (de) Verfahren zur herstellung einer zusammensetzung enthaltend hyaluronsäure
EP3731806B1 (de) Verfahren zur herstellung eines füllstoffs mit einer hyaluronsäurebasis
EP3731805B1 (de) Verfahren zur herstellung eines füllstoffs mit einer hyaluronsäurebasis unter verwendung spezieller vernetzungsmittel
US9220807B2 (en) Non-toxic cross-linker for hyaluronic acid
RU2780323C2 (ru) Способ получения наполнителя на основе гиалуроновой кислоты с использованием специфических сшивающих агентов
RU2790229C2 (ru) Способ получения наполнителя на основе гиалуроновой кислоты, включающий стадию нейтрализации
US20150190517A1 (en) Systems and methods for delivering cross-linked halyuronic acid into a patient
CN115869250A (zh) 一种注射用透明质酸或透明质酸钠组合物及其制备方法和用途

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200728

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220302

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1500826

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017059096

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220929

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220930

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220929

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20220629

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1500826

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221031

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221029

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017059096

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20230330

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20221231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221229

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231211

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231106

Year of fee payment: 7

Ref country code: FR

Payment date: 20231211

Year of fee payment: 7

Ref country code: DE

Payment date: 20231208

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240102

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20171229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220629